Search results
Weight loss medication complete guide: From Wegovy to Mounjaro
The Telegraph via Yahoo News· 13 hours agoThe new generation of weight-loss drugs were initially developed to treat diabetes and work by...
Is oral semaglutide a promising alternative in treating diabetes, heart disease?
MedicalNewsToday via AOL· 13 hours agoOral semaglutide may be a promising alternative “Having semaglutide available as an oral or...
Britain considers offering Lilly weight-loss drug on better terms than Wegovy
Reuters via AOL· 1 day agoOnce approved, the draft recommendations from the National Institute for Health and Care Excellence...
Compounding pharmacies are making their own versions of blockbuster weight loss drugs
KTEP 88.5 El Paso· 6 days agoAs more people turn to blockbuster drugs like Wegovy to lose weight, some are choosing to skip the name-brand drugs and go online for less expensive alternatives made by specialized ...
Diabetes drug recommended to treat obesity on the NHS
Press Association News via AOL· 2 days agoOther GLP-1 agonists include semaglutide – sold under the brand names Wegovy, Ozempic and Rybelsus....
Dangerously obese people to be offered new powerful weight loss jab on NHS
Daily Express· 17 hours agoAnother step in the fight against the obesity epidemic in the UK has been taken as a powerful...
Moms say their weight-loss drugs had a trickle-down effect — making their entire families healthier
Business Insider· 6 days agoThis story is available exclusively to Business Insider subscribers. Become an Insider and start...
Eli Lilly's Wegovy rival Zepbound will help make weight-loss drug market worth $130 billion by 2030,...
Business Insider· 4 days agoThe anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs analysts said in a...
New Oral Weight Loss Drugs: Where Are We and What's Next?
Medscape· 20 hours agoNow that semaglutide (Wegovy), tirzepatide (Zepbound), and other injectables have created an...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 3 days agoFor now, those benefits are not proven, and the company hasn't released much in the way of...